tiprankstipranks

Steve E. Krognes Insider Profile

4 Followers
Steve E. Krognes, Director at Denali Therapeutics, holds 897.34K shares in Denali Therapeutics (Ticker: DNLI), holds ― shares in Corvus Pharmaceuticals (Ticker: CRVS), holds ― shares in Gritstone Oncology (Ticker: GRTS).
tipranks
Steve E. Krognes

Steve E. Krognes
Denali Therapeutics (DNLI)
Director

Ranked #52,098 out of 98,743 Corporate Insiders

Profitable Transactions

71%
10 out of 14 Profitable Transactions

Average Return

-0.70%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$15M
99.58%
0.42%
0.00%
0.00%
A breakdown of Steve E. Krognes's holdings

Insider Roles

Denali Therapeutics
(DNLI)
Director
Guardant Health
(GH)
Director
Corvus Pharmaceuticals
(CRVS)
Director
Gritstone Oncology
(GRTS)
Director
Roles that Steve E. Krognes holds in companies

Most Profitable Insider Trade

Stock:
Denali Therapeutics
(DNLI)
Rating:Informative Sell
Date:Feb 16, 2021 - Feb 16, 2022
Return:+44.30%
The most profitable trade made by Steve E. Krognes

Steve E. Krognes's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
Denali Therapeutics
Apr 02, 2024
Director
Uninformative Sell
1.90M
$15.12M
Corvus Pharmaceuticals
Director
Gritstone Oncology
Director
Guardant Health
May 02, 2024
Director
Uninformative Buy
$63.86K
List of latest transactions for each holding click on a transaction to see Steve E. Krognes's performance on stock

Steve E. Krognes insider profile FAQ

What is the percentage of profitable transactions made by Steve E. Krognes?
The percentage of profitable transactions made by Steve E. Krognes is 71%.
    What is the average return per transaction made by Steve E. Krognes?
    The average return per transaction made by Steve E. Krognes is -0.70%.
      What stocks does Steve E. Krognes hold?
      Steve E. Krognes holds: DNLI, CRVS, GRTS, GH stocks.
        What was Steve E. Krognes’s latest transaction?
        Steve E. Krognes latest transaction was an Uninformative Sell of $1.90M.
          What was Steve E. Krognes's most profitable transaction?
          Steve E. Krognes’s most profitable transaction was an Informative Sell of DNLI stock on February 16, 2021. The return on the trade was 44.30%.
            What is Steve E. Krognes's role in Denali Therapeutics?
            Steve E. Krognes's role in Denali Therapeutics is Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.